View Future GrowthSimris Group 過去の業績過去 基準チェック /06Simris Groupの収益は年間平均-3.3%の割合で減少していますが、 Personal Products業界の収益は年間 増加しています。収益は年間10.5% 16%割合で 減少しています。主要情報-3.32%収益成長率40.16%EPS成長率Personal Products 業界の成長8.70%収益成長率-15.97%株主資本利益率-492.22%ネット・マージン-1,020.52%次回の業績アップデート12 Aug 2026最近の業績更新お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026お知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).すべての更新を表示Recent updatesお知らせ • May 22Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026, at 16:00 W. Europe Standard Time. Location: at the offices of advokatfirman delphi, nordenskioldsgatan 11 a, 211 19, malmo Swedenお知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.お知らせ • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.お知らせ • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo Swedenお知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.お知らせ • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).お知らせ • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024お知らせ • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.お知らせ • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.New Risk • Feb 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Share price has been highly volatile over the past 3 months (1,530% average daily change). Earnings have declined by 5.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (kr5.2m revenue, or US$498k). Market cap is less than US$10m (€6.83m market cap, or US$7.40m).Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).お知らせ • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.Recent Insider Transactions • Sep 27Independent Chairman recently bought €541k worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly €0.023 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €753k worth in shares.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (133% average daily change). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (€7.03m market cap, or US$7.50m).お知らせ • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).お知らせ • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).Reported Earnings • Feb 18Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).お知らせ • Aug 17Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH.Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH on June 12, 2022. The purchase price will include a combination of cash payments, Simris shares and performance related payments. The deal is subject to customary due diligence which is also due complete at a similar time and is due to complete by end of AugustRecent Insider Transactions • May 17Interim Executive Chairman recently bought €98k worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly €0.03 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €112k worth in shares.Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).お知らせ • Apr 23+ 4 more updatesSimris Alg AB (Publ) Appoints Julian Read as Chief Executive Officer, Effective on May 16, 2022Simris Alg AB (publ) appointed Julian Read as CEO starting May 16, 2022. Julian was most recently Managing Director (Nordics) for Dyson, and before that marketing director (Nordics) for Omega Pharma.Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020).Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (€114k worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020).Reported Earnings • Apr 21Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019).お知らせ • Aug 16Simris Alg AB (publ) to Report Q2, 2020 Results on Aug 18, 2020Simris Alg AB (publ) announced that they will report Q2, 2020 results at 8:00 AM, Central European Standard Time on Aug 18, 2020収支内訳Simris Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:5LU 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 263-2718031 Dec 252-2719030 Sep 252-2917030 Jun 253-2915031 Mar 253-3117031 Dec 243-3519030 Sep 245-3521030 Jun 244-3624031 Mar 244-3725031 Dec 234-3725030 Sep 232-3725030 Jun 232-3523031 Mar 231-3021031 Dec 224-2418030 Sep 227-1915030 Jun 228-2317031 Mar 229-2619031 Dec 216-2821030 Sep 214-3324030 Jun 213-2722031 Mar 213-2619031 Dec 202-2619030 Sep 202-2518030 Jun 201-2724031 Mar 201-2823031 Dec 192-2720030 Sep 192-2627030 Jun 192-2619031 Mar 192-2319031 Dec 181-2419030 Sep 181-2419030 Jun 181-2321031 Mar 181-2321031 Dec 171-2322030 Sep 171-2319030 Jun 171-2118031 Mar 171-2017031 Dec 161-1916030 Sep 161-1613030 Jun 161-1513031 Mar 161-1412031 Dec 151-12120質の高い収益: 5LUは現在利益が出ていません。利益率の向上: 5LUは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 5LUは利益が出ておらず、過去 5 年間で損失は年間3.3%の割合で増加しています。成長の加速: 5LUの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 5LUは利益が出ていないため、過去 1 年間の収益成長をPersonal Products業界 ( 2.7% ) と比較することは困難です。株主資本利益率高いROE: 5LUは現在利益が出ていないため、自己資本利益率 ( -492.22% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 09:42終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Simris Group AB (PUBL) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026
お知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025
Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).
お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).
お知らせ • May 22Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026, at 16:00 W. Europe Standard Time. Location: at the offices of advokatfirman delphi, nordenskioldsgatan 11 a, 211 19, malmo Sweden
お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026
お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.
お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
お知らせ • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.
お知らせ • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo Sweden
お知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025
Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
お知らせ • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.
Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).
お知らせ • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.
Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.
お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024
お知らせ • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.
お知らせ • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.
New Risk • Feb 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Share price has been highly volatile over the past 3 months (1,530% average daily change). Earnings have declined by 5.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (kr5.2m revenue, or US$498k). Market cap is less than US$10m (€6.83m market cap, or US$7.40m).
Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).
お知らせ • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.
Recent Insider Transactions • Sep 27Independent Chairman recently bought €541k worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly €0.023 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €753k worth in shares.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (133% average daily change). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (€7.03m market cap, or US$7.50m).
お知らせ • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.
Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).
お知らせ • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023
Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).
Reported Earnings • Feb 18Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).
Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).
お知らせ • Aug 17Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH.Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH on June 12, 2022. The purchase price will include a combination of cash payments, Simris shares and performance related payments. The deal is subject to customary due diligence which is also due complete at a similar time and is due to complete by end of August
Recent Insider Transactions • May 17Interim Executive Chairman recently bought €98k worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly €0.03 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €112k worth in shares.
Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).
お知らせ • Apr 23+ 4 more updatesSimris Alg AB (Publ) Appoints Julian Read as Chief Executive Officer, Effective on May 16, 2022Simris Alg AB (publ) appointed Julian Read as CEO starting May 16, 2022. Julian was most recently Managing Director (Nordics) for Dyson, and before that marketing director (Nordics) for Omega Pharma.
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020).
Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (€114k worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020).
Reported Earnings • Apr 21Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019).
お知らせ • Aug 16Simris Alg AB (publ) to Report Q2, 2020 Results on Aug 18, 2020Simris Alg AB (publ) announced that they will report Q2, 2020 results at 8:00 AM, Central European Standard Time on Aug 18, 2020